Home » Topics » Regulatory » EMA

EMA
RSS

New Juvista formulation for children significantly improves scar appearance

Nov. 23, 2010

CIS Bio withdraws E.U. marketing authorization for NeoSpect

Nov. 23, 2010

EMA's COMP recommends orphan status for paquinimod in systemic sclerosis

Nov. 18, 2010

EMA accepts Pixuvri MAA for non-Hodgkin's lymphoma for review

Nov. 18, 2010

Roche reports on third quarter of 2010

Nov. 18, 2010

EMA approves Cell Therapeutics' pediatric investigation plan for Pixuvri

Nov. 17, 2010

EMA orphan drug status for SBC-102 in LAL deficiency / News in Context

Nov. 17, 2010

EMA committee recommends orphan drug status for ThermoDox in primary liver cancer

Nov. 12, 2010

Schering-Plough Europe withdraws MAA for Zenhale

Nov. 11, 2010

MabThera approved in E.U. as maintenance treatment of follicular lymphoma

Nov. 4, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...